Q-omics provides the consensus-scored MASP2 profile across patient tissues and cancer cell-line models. MASP2 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MASP2 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, MASP2 RNA expression shows 20,979 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where MASP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MASP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MASP2 survival associations across molecular data types. MASP2 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MASP2 RNA expression–survival associations across cancer types. High MASP2 expression shows favorable associations in HNSC, READ, LIHC, KIRP, UCS and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MASP2 RNA expression.
This table summarizes MASP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MASP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MASP2 shows lower tumor expression in THCA, LUAD, BRCA, LUSC, KIRP and CHOL. The THCA box plot shows higher MASP2 RNA expression in normal versus tumor tissue (log2 FC = −0.507, t-test p < 0.001).
This table shows molecular features associated with MASP2 in patient tissues and cancer cell lines. In patient samples, MASP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MASP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
